{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:18:12Z","timestamp":1776871092774,"version":"3.51.2"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81672041"],"award-info":[{"award-number":["81672041"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Reactivation of hepatitis B virus is a common complication that occurs in patients with hepatitis B virus (HBV) infection who have received cytotoxic chemotherapy or immunosuppressive therapy. This clinical phenomenon not only occurs in overt HBV infection patients but also occurs in patients with resolved HBV infection. Previous research has confirmed that epirubicin and dexamethasone can stimulate HBV replication and expression directly rather than indirectly through immunosuppression. Mitomycin and 5-fluorouracil are currently used as cytotoxic chemotherapy drugs for cancer patients. Leflunomide and mycophenolic acid are regarded as immunosuppressants for autoimmune diseases, and numerous clinical studies have reported that these drugs can reactivate HBV replication. In this study, we aimed to investigate whether mitomycin, 5-fluorouracil, leflunomide and mycophenolic acid induce HBV reactivation directly rather than indirectly through immunosuppression.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>To observe the effect of mitomycin, 5-fluorouracil, leflunomide and mycophenolic acid on HBV replication and expression, we employed HepG2.2.15 and HBV-NLuc-35 cells as a cell model. Next, by native agarose gel electrophoresis (NAGE), quantitative PCR (qPCR), luciferase assay and HBV e antigen (HBeAg) enzyme-linked immunosorbent assay (ELISA) we detected changes in HBV replication and expression induced by these drugs. We also investigated whether lamivudine could inhibit the observed phenotype. SPSS 18.0 software was employed for statistical analysis, One-way ANOVA was used to compare multiple groups.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Expression of HBV capsids and HBeAg in HepG2.2.15 cells was increased by increasing concentration of mitomycin, 5-fluorouracil, leflunomide, and mycophenolic acid. This phenomenon was also demonstrated in HBV-NLuc-35 cells, and the expression of capsids and luciferase activity increased in the same concentration-dependent manner. Replication levels of intracellular capsid DNA and extracellular HBV DNA in HepG2.2.15 cells gradually increased in a dose-dependent manner. In addition, although epirubicin, mitomycin, 5-fluorouracil, dexamethasone, leflunomide and mycophenolic acid enhanced HBV replication, lamivudine inhibited this process.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Our study confirmed that mitomycin, 5-fluorouracil, leflunomide and mycophenolic acid directly upregulated HBV replication and expression in vitro. This effect was investigated not only in HepG2.2.15 cells but also in the HBV-NLuc-35 replication system. Moreover, this effect could be prevented by nucleoside analogs, such as lamivudine (LAM). Thus, for patients with HBV infection, prophylactic antiviral therapy is necessary before receiving cytotoxic chemotherapy or immunosuppressive therapy.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12985-020-01339-5","type":"journal-article","created":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T21:38:36Z","timestamp":1593639516000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Mitomycin, 5-fluorouracil, leflunomide, and mycophenolic acid directly promote hepatitis B virus replication and expression in vitro"],"prefix":"10.1186","volume":"17","author":[{"given":"Jie","family":"Ruan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengyu","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinge","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dianxing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,1]]},"reference":[{"issue":"1","key":"1339_CR1","first-page":"61","volume":"45","author":"I Wijaya","year":"2013","unstructured":"Wijaya I, Hasan I. Reactivation of hepatitis B virus associated with chemotherapy and immunosuppressive agent. Acta Med Indones. 2013;45(1):61\u20136 [PMID: 23585411].","journal-title":"Acta Med Indones"},{"key":"1339_CR2","doi-asserted-by":"publisher","unstructured":"Cheung KS, Seto WK, Lai CL, Yuen MF. Prevention and management of hepatitis B virus reactivation in cancer patients. Hepatol Int. 2016 [PMID: 26739135. https:\/\/doi.org\/10.1007\/s12072-015-9692-3.","DOI":"10.1007\/s12072-015-9692-3"},{"issue":"1","key":"1339_CR3","doi-asserted-by":"publisher","first-page":"64","DOI":"10.7326\/M15-2722","volume":"164","author":"V Lo Re 3rd","year":"2016","unstructured":"Lo Re V 3rd, Schuster M. Evaluating hepatitis B virus reactivation during solid tumor chemotherapy: evidence to guide pretreatment hepatitis B screening and prophylaxis. Ann Intern Med. 2016;164(1):64\u20135 [PMID: 26595449. https:\/\/doi.org\/10.7326\/M15-2722.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1339_CR4","doi-asserted-by":"publisher","first-page":"30","DOI":"10.7326\/M15-1121","volume":"164","author":"S Paul","year":"2016","unstructured":"Paul S, Saxena A, Terrin N, Viveiros K, Balk EM, Wong JB. Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy: a systematic review and meta-analysis. Ann Intern Med. 2016;164(1):30\u201340 [PMID: 26595058. https:\/\/doi.org\/10.7326\/M15-1121.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1339_CR5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0016-5085(75)80054-0","volume":"68","author":"JR Wands","year":"1975","unstructured":"Wands JR, Chura CM, Roll FJ, Maddrey WC. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology. 1975;68(1):105\u201312 PMID: 1054319.","journal-title":"Gastroenterology"},{"issue":"4","key":"1339_CR6","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1053\/gast.2001.22461","volume":"120","author":"RP Perrillo","year":"2001","unstructured":"Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology. 2001;120(4):1009\u201322 PMID: 11231956.","journal-title":"Gastroenterology"},{"issue":"4","key":"1339_CR7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nrgastro.2013.216","volume":"11","author":"JP Hwang","year":"2014","unstructured":"Hwang JP, Lok AS. Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol. 2014;11(4):209\u201319 [PMID: 24247262 PMCID: 4170710. https:\/\/doi.org\/10.1038\/nrgastro.2013.216.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"1339_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1093\/jjco\/hys191","volume":"43","author":"M Ikeda","year":"2013","unstructured":"Ikeda M. Reactivation of hepatitis B virus in patients receiving chemotherapy. Jpn J Clin Oncol. 2013;43(1):8\u201316 [PMID: 23183929. https:\/\/doi.org\/10.1093\/jjco\/hys191.","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"1339_CR9","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s12072-011-9279-6","volume":"7","author":"CJ Liu","year":"2013","unstructured":"Liu CJ, Chen PJ, Chen DS, Kao JH. Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management. Hepatol Int. 2013;7(2):316\u201326 [PMID: 21670970. https:\/\/doi.org\/10.1007\/s12072-011-9279-6.","journal-title":"Hepatol Int"},{"issue":"7","key":"1339_CR10","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/j.1872-034X.2012.00998.x","volume":"42","author":"M Oketani","year":"2012","unstructured":"Oketani M, Ido A, Uto H, Tsubouchi H. Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. Hepatol Res. 2012;42(7):627\u201336 [PMID: 22686858. https:\/\/doi.org\/10.1111\/j.1872-034X.2012.00998.x.","journal-title":"Hepatol Res"},{"issue":"2","key":"1339_CR11","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/hep.27609","volume":"61","author":"AM Di Bisceglie","year":"2015","unstructured":"Di Bisceglie AM, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology. 2015;61(2):703\u201311 [PMID: 25412906. https:\/\/doi.org\/10.1002\/hep.27609.","journal-title":"Hepatology"},{"issue":"5 Suppl","key":"1339_CR12","doi-asserted-by":"publisher","first-page":"S156","DOI":"10.1002\/hep.22945","volume":"49","author":"JH Hoofnagle","year":"2009","unstructured":"Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009;49(5 Suppl):S156\u201365 [PMID: 19399803. https:\/\/doi.org\/10.1002\/hep.22945.","journal-title":"Hepatology"},{"issue":"1","key":"1339_CR13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/0168-8278(90)90268-V","volume":"11","author":"R Tur-Kaspa","year":"1990","unstructured":"Tur-Kaspa R, Laub O. Corticosteroids stimulate hepatitis B virus DNA, mRNA and protein production in a stable expression system. J Hepatol. 1990;11(1):34\u20136 PMID: 2168915.","journal-title":"J Hepatol"},{"issue":"6","key":"1339_CR14","doi-asserted-by":"publisher","first-page":"e0131743","DOI":"10.1371\/journal.pone.0131743","volume":"10","author":"YF Chen","year":"2015","unstructured":"Chen YF, Chong CL, Wu YC, Wang YL, Tsai KN, Kuo TM, Hong MH, Hu CP, Chen ML, Chou YC, Chang C. Doxorubicin Activates Hepatitis B Virus Replication by Elevation of p21 (Waf1\/Cip1) and C\/EBPalpha Expression. PloS one. 2015;10(6):e0131743 [PMID: 26121644 PMCID: 4486450. https:\/\/doi.org\/10.1371\/journal.pone.0131743.","journal-title":"PloS one"},{"issue":"5A","key":"1339_CR15","first-page":"3035","volume":"24","author":"CH Hsu","year":"2004","unstructured":"Hsu CH, Hsu HC, Chen HL, Gao M, Yeh PY, Chen PJ, Cheng AL. Doxorubicin activates hepatitis B virus (HBV) replication in HBV-harboring hepatoblastoma cells. A possible novel mechanism of HBV reactivation in HBV carriers receiving systemic chemotherapy. Anticancer Res. 2004;24(5A):3035\u201340 PMID: 15517913.","journal-title":"Anticancer Res"},{"issue":"11","key":"1339_CR16","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1093\/annonc\/mdh430","volume":"15","author":"W Yeo","year":"2004","unstructured":"Yeo W, Lam KC, Zee B, Chan PS, Mo FK, Ho WM, Wong WL, Leung TW, Chan AT, Ma B, Mok TS, Johnson PJ. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol. 2004;15(11):1661\u20136 [PMID: 15520068. https:\/\/doi.org\/10.1093\/annonc\/mdh430.","journal-title":"Ann Oncol"},{"issue":"2","key":"1339_CR17","doi-asserted-by":"publisher","first-page":"320","DOI":"10.12669\/pjms.312.6673","volume":"31","author":"H Ming-Xu","year":"2015","unstructured":"Ming-Xu H, Chen M, Cai Y, Yan-Jia H. Clinical outcomes of low-dose leflunomide for rheumatoid arthritis complicated with Hepatitis B virus carriage and safety observation. Pak J Med Sci. 2015;31(2):320\u20134 [PMID: 26101483 PMCID: 4476334. https:\/\/doi.org\/10.12669\/pjms.312.6673.","journal-title":"Pak J Med Sci"},{"issue":"3","key":"1339_CR18","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1345\/aph.1E419","volume":"39","author":"H Sayarlioglu","year":"2005","unstructured":"Sayarlioglu H, Erkoc R, Dogan E, Sayarlioglu M, Topal C. Mycophenolate mofetil use in hepatitis B associated-membranous and membranoproliferative glomerulonephritis induces viral replication. Ann Pharmacother. 2005;39(3):573 [PMID: 15671086. https:\/\/doi.org\/10.1345\/aph.1E419.","journal-title":"Ann Pharmacother"},{"issue":"4","key":"1339_CR19","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1073\/pnas.84.4.1005","volume":"84","author":"MA Sells","year":"1987","unstructured":"Sells MA, Chen ML, Acs G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Nat Acad Sci U S A. 1987;84(4):1005\u20139 [PMID: 3029758 PMCID: 304350. https:\/\/doi.org\/10.1073\/pnas.84.4.1005.","journal-title":"Proc Nat Acad Sci U S A"},{"issue":"39","key":"1339_CR20","doi-asserted-by":"publisher","first-page":"5961","DOI":"10.3748\/wjg.v25.i39.5961","volume":"25","author":"J Ruan","year":"2019","unstructured":"Ruan J, Ping CY, Sun S, Cheng X, Han PY, Zhang YG, Sun DX. Construction of a replication-competent hepatitis B virus vector carrying secreted luciferase transgene and establishment of new hepatitis B virus replication and expression cell lines. World J Gastroenterol. 2019;25(39):5961\u201372 [PMID: 31660033 PMCID: 6815792. https:\/\/doi.org\/10.3748\/wjg.v25.i39.5961.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"1339_CR21","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.jhep.2006.05.019","volume":"45","author":"D Sun","year":"2006","unstructured":"Sun D, Nassal M. Stable HepG2- and Huh7-based human hepatoma cell lines for efficient regulated expression of infectious hepatitis B virus. J Hepatol. 2006;45(5):636\u201345 [PMID: 16935386. https:\/\/doi.org\/10.1016\/j.jhep.2006.05.019.","journal-title":"J Hepatol"},{"issue":"4","key":"1339_CR22","doi-asserted-by":"publisher","first-page":"e60306","DOI":"10.1371\/journal.pone.0060306","volume":"8","author":"Z Wang","year":"2013","unstructured":"Wang Z, Wu L, Cheng X, Liu S, Li B, Li H, Kang F, Wang J, Xia H, Ping C, Nassal M, Sun D. Replication-competent infectious hepatitis B virus vectors carrying substantially sized transgenes by redesigned viral polymerase translation. PloS one. 2013;8(4):e60306 [PMID: 23589756 PMCID: 3615001. https:\/\/doi.org\/10.1371\/journal.pone.0060306.","journal-title":"PloS one"},{"issue":"7","key":"1339_CR23","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1128\/JVI.64.7.3319-3330.1990","volume":"64","author":"F Birnbaum","year":"1990","unstructured":"Birnbaum F, Nassal M. Hepatitis B virus nucleocapsid assembly: primary structure requirements in the core protein. J Virol. 1990;64(7):3319\u201330 PMID: 2191149 PMCID: 249568.","journal-title":"J Virol"},{"issue":"3","key":"1339_CR24","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1128\/JVI.75.3.1104-1116.2001","volume":"75","author":"S Ren","year":"2001","unstructured":"Ren S, Nassal M. Hepatitis B virus (HBV) virion and covalently closed circular DNA formation in primary tupaia hepatocytes and human hepatoma cell lines upon HBV genome transduction with replication-defective adenovirus vectors. J Virol. 2001;75(3):1104\u201316 [PMID: 11152483 PMCID: 114016. https:\/\/doi.org\/10.1128\/JVI.75.3.1104-1116.2001.","journal-title":"J Virol"},{"issue":"10","key":"1339_CR25","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.3899\/jrheum.110289","volume":"38","author":"M Kato","year":"2011","unstructured":"Kato M, Atsumi T, Kurita T, Odani T, Fujieda Y, Otomo K, Horita T, Yasuda S, Koike T. Hepatitis B virus reactivation by immunosuppressive therapy in patients with autoimmune diseases: risk analysis in Hepatitis B surface antigen-negative cases. J Rheumatol. 2011;38(10):2209\u201314 [PMID: 21844146. https:\/\/doi.org\/10.3899\/jrheum.110289.","journal-title":"J Rheumatol"},{"issue":"12","key":"1339_CR26","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.3748\/wjg.v17.i12.1531","volume":"17","author":"ML Manzano-Alonso","year":"2011","unstructured":"Manzano-Alonso ML, Castellano-Tortajada G. Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy. World J Gastroenterol. 2011;17(12):1531\u20137 [PMID: 21472116 PMCID: 3070121. https:\/\/doi.org\/10.3748\/wjg.v17.i12.1531.","journal-title":"World J Gastroenterol"},{"issue":"10","key":"1339_CR27","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s00277-011-1241-0","volume":"90","author":"YX Koo","year":"2011","unstructured":"Koo YX, Tay M, Teh YE, Teng D, Tan DS, Tan IB, Tai DW, Quek R, Tao M, Lim ST. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative\/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Ann Hematol. 2011;90(10):1219\u201323 [PMID: 21520001. https:\/\/doi.org\/10.1007\/s00277-011-1241-0.","journal-title":"Ann Hematol"},{"issue":"3","key":"1339_CR28","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0","volume":"62","author":"W Yeo","year":"2000","unstructured":"Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, Hui P, Leung NW, Zee B, Johnson PJ. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000;62(3):299\u2013307 PMID: 11055239.","journal-title":"J Med Virol"},{"issue":"Suppl 1","key":"1339_CR29","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1023\/A:1008234807768","volume":"8","author":"K Kumagai","year":"1997","unstructured":"Kumagai K, Takagi T, Nakamura S, Sawada U, Kura Y, Kodama F, Shimano S, Kudoh I, Nakamura H, Sawada K, Ohnoshi T. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol. 1997;8(Suppl 1):107\u20139 PMID: 9187442.","journal-title":"Ann Oncol"},{"issue":"10","key":"1339_CR30","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1002\/(SICI)1097-0142(19961115)78:10<2210::AID-CNCR24>3.0.CO;2-0","volume":"78","author":"Y Nakamura","year":"1996","unstructured":"Nakamura Y, Motokura T, Fujita A, Yamashita T, Ogata E. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991. Cancer. 1996;78(10):2210\u20135 PMID: 8918416.","journal-title":"Cancer"},{"issue":"1","key":"1339_CR31","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1440-1746.1998.tb00539.x","volume":"13","author":"YF Liaw","year":"1998","unstructured":"Liaw YF. Hepatitis viruses under immunosuppressive agents. J Gastroenterol Hepatol. 1998;13(1):14\u201320 PMID: 9737566.","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"1339_CR32","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00280-015-2700-4","volume":"75","author":"Y Yang","year":"2015","unstructured":"Yang Y, Du Y, Luo WX, Li C, Chen Y, Cheng K, Ding J, Zhou Y, Ge J, Yang X, Liu JY. Hepatitis B virus reactivation and hepatitis in gastrointestinal cancer patients after chemotherapy. Cancer Chemother Pharmacol. 2015;75(4):783\u201390 [PMID: 25687988. https:\/\/doi.org\/10.1007\/s00280-015-2700-4.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"1339_CR33","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s12032-014-0119-0","volume":"31","author":"GN Lin","year":"2014","unstructured":"Lin GN, Peng JW, Xiao JJ, Liu DY, Xia ZJ. Hepatitis B virus reactivation in hepatitis B surface antigen seropositive patients with metastatic non-small cell lung cancer receiving cytotoxic chemotherapy: the efficacy of preemptive lamivudine and identification of risk factors. Med Oncol. 2014;31(8):119 [PMID: 25023055. https:\/\/doi.org\/10.1007\/s12032-014-0119-0.","journal-title":"Med Oncol"},{"issue":"1","key":"1339_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s004320050235","volume":"125","author":"F Castaneda","year":"1999","unstructured":"Castaneda F, Kinne RK. Effects of doxorubicin, mitomycin C, and ethanol on Hep-G2 cells in vitro. J Cancer Res Clin Oncol. 1999;125(1):1\u20138 [PMID: 10037271. https:\/\/doi.org\/10.1007\/s004320050235.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"1339_CR35","doi-asserted-by":"publisher","first-page":"637","DOI":"10.2217\/imt.10.52","volume":"2","author":"S Teschner","year":"2010","unstructured":"Teschner S, Burst V. Leflunomide: a drug with a potential beyond rheumatology. Immunotherapy. 2010;2(5):637\u201350 [PMID: 20874647. https:\/\/doi.org\/10.2217\/imt.10.52.","journal-title":"Immunotherapy"},{"issue":"Suppl 1","key":"1339_CR36","doi-asserted-by":"publisher","first-page":"s2","DOI":"10.1177\/096120330501400102","volume":"14","author":"AC Allison","year":"2005","unstructured":"Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus. 2005;14(Suppl 1):s2\u20138 PMID: 15803924.","journal-title":"Lupus"},{"key":"1339_CR37","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.antiviral.2015.02.002","volume":"118","author":"LK Jeffers-Francis","year":"2015","unstructured":"Jeffers-Francis LK, Burger-Calderon R, Webster-Cyriaque J. Effect of Leflunomide, Cidofovir and Ciprofloxacin on replication of BKPyV in a salivary gland in vitro culture system. Antiviral Res. 2015;118:46\u201355 [PMID: 25790744 PMCID: 4424161. https:\/\/doi.org\/10.1016\/j.antiviral.2015.02.002.","journal-title":"Antiviral Res"},{"issue":"1","key":"1339_CR38","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/01.TP.0000149338.97084.5F","volume":"79","author":"NA Farasati","year":"2005","unstructured":"Farasati NA, Shapiro R, Vats A, Randhawa P. Effect of leflunomide and cidofovir on replication of BK virus in an in vitro culture system. Transplantation. 2005;79(1):116\u20138 PMID: 15714178.","journal-title":"Transplantation"},{"issue":"5\u20136","key":"1339_CR39","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1159\/000053979","volume":"42","author":"WJ Waldman","year":"1999","unstructured":"Waldman WJ, Knight DA, Blinder L, Shen J, Lurain NS, Miller DM, Sedmak DD, Williams JW, Chong AS. Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide. Intervirology. 1999;42(5\u20136):412\u20138 PMID: 10702725 doi: 53979.","journal-title":"Intervirology"},{"issue":"1","key":"1339_CR40","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/00007890-200101150-00031","volume":"71","author":"DA Knight","year":"2001","unstructured":"Knight DA, Hejmanowski AQ, Dierksheide JE, Williams JW, Chong AS, Waldman WJ. Inhibition of herpes simplex virus type 1 by the experimental immunosuppressive agent leflunomide. Transplantation. 2001;71(1):170\u20134 PMID: 11211189.","journal-title":"Transplantation"},{"issue":"11","key":"1339_CR41","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1097\/01.aids.0000072664.21517.ad","volume":"17","author":"E Schlapfer","year":"2003","unstructured":"Schlapfer E, Fischer M, Ott P, Speck RF. Anti-HIV-1 activity of leflunomide: a comparison with mycophenolic acid and hydroxyurea. AIDS. 2003;17(11):1613\u201320 [PMID: 12853743. https:\/\/doi.org\/10.1097\/01.aids.0000072664.21517.ad.","journal-title":"AIDS"},{"issue":"3","key":"1339_CR42","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3851\/IMP1763","volume":"16","author":"MC Dunn","year":"2011","unstructured":"Dunn MC, Knight DA, Waldman WJ. Inhibition of respiratory syncytial virus in vitro and in vivo by the immunosuppressive agent leflunomide. Antiviral Ther. 2011;16(3):309\u201317 [PMID: 21555813. https:\/\/doi.org\/10.3851\/IMP1763.","journal-title":"Antiviral Ther"},{"issue":"2","key":"1339_CR43","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1006\/viro.2002.1685","volume":"304","author":"MS Diamond","year":"2002","unstructured":"Diamond MS, Zachariah M, Harris E. Mycophenolic acid inhibits dengue virus infection by preventing replication of viral RNA. Virology. 2002;304(2):211\u201321 PMID: 12504563.","journal-title":"Virology"},{"issue":"1","key":"1339_CR44","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.antiviral.2004.05.004","volume":"64","author":"CM Robertson","year":"2004","unstructured":"Robertson CM, Hermann LL, Coombs KM. Mycophenolic acid inhibits avian reovirus replication. Antiviral Res. 2004;64(1):55\u201361 [PMID: 15451179. https:\/\/doi.org\/10.1016\/j.antiviral.2004.05.004.","journal-title":"Antiviral Res"},{"issue":"3","key":"1339_CR45","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1128\/JVI.79.3.1943-1947.2005","volume":"79","author":"P Leyssen","year":"2005","unstructured":"Leyssen P, Balzarini J, De Clercq E, Neyts J. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol. 2005;79(3):1943\u20137 [PMID: 15650220 PMCID: 544097. https:\/\/doi.org\/10.1128\/JVI.79.3.1943-1947.2005.","journal-title":"J Virol"},{"issue":"1","key":"1339_CR46","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0166-3542(02)00013-X","volume":"55","author":"JD Morrey","year":"2002","unstructured":"Morrey JD, Smee DF, Sidwell RW, Tseng C. Identification of active antiviral compounds against a New York isolate of West Nile virus. Antivir Res. 2002;55(1):107\u201316 PMID: 12076755.","journal-title":"Antivir Res"},{"issue":"1","key":"1339_CR47","first-page":"35","volume":"27","author":"H Chen","year":"2013","unstructured":"Chen H, Ye L, Su JM, Li Y, Zeng JR, Huo WZ. Inhibition of hepatitis C virus replication by mycophenolic acid in hepatocytes. Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology. 2013;27(1):35\u20138 PMID: 23855126.","journal-title":"Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology"},{"issue":"6","key":"1339_CR48","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1002\/hep.25562","volume":"55","author":"Q Pan","year":"2012","unstructured":"Pan Q, de Ruiter PE, Metselaar HJ, Kwekkeboom J, de Jonge J, Tilanus HW, Janssen HL, van der Laan LJ. Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C Virus infection in vitro and in vivo. Hepatology. 2012;55(6):1673\u201383 [PMID: 22213147. https:\/\/doi.org\/10.1002\/hep.25562.","journal-title":"Hepatology"},{"issue":"5","key":"1339_CR49","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1053\/j.gastro.2006.08.027","volume":"131","author":"SD Henry","year":"2006","unstructured":"Henry SD, Metselaar HJ, Lonsdale RC, Kok A, Haagmans BL, Tilanus HW, van der Laan LJ. Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha. Gastroenterology. 2006;131(5):1452\u201362 [PMID: 17101321. https:\/\/doi.org\/10.1053\/j.gastro.2006.08.027.","journal-title":"Gastroenterology"},{"issue":"7","key":"1339_CR50","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1053\/j.gastro.2014.02.036","volume":"146","author":"Y Wang","year":"2014","unstructured":"Wang Y, Zhou X, Debing Y, Chen K, Van Der Laan LJ, Neyts J, Janssen HL, Metselaar HJ, Peppelenbosch MP, Pan Q. Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus. Gastroenterology. 2014;146(7):1775\u201383 [PMID: 24582714. https:\/\/doi.org\/10.1053\/j.gastro.2014.02.036.","journal-title":"Gastroenterology"},{"issue":"3","key":"1339_CR51","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1046\/j.1365-2893.1999.00163.x","volume":"6","author":"ZJ Gong","year":"1999","unstructured":"Gong ZJ, De Meyer S, Clarysse C, Verslype C, Neyts J, De Clercq E, Yap SH. Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro. J Viral Hepat. 1999;6(3):229\u201336 PMID: 10607235.","journal-title":"J Viral Hepat"},{"issue":"3","key":"1339_CR52","first-page":"410","volume":"2","author":"J Wu","year":"2003","unstructured":"Wu J, Xie HY, Jiang GP, Xu X, Zheng SS. The effect of mycophenolate acid on hepatitis B virus replication in vitro. Hepatobiliary Pancreat Dis Int. 2003;2(3):410\u20133 PMID: 14599949.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"1","key":"1339_CR53","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1365-2893.2012.01622.x","volume":"20","author":"M Mouler Rechtman","year":"2013","unstructured":"Mouler Rechtman M, Burdelova EO, Bar-Yishay I, Ben-Yehoyada M, Fishman S, Halpern Z, Shlomai A. The metabolic regulator PGC-1alpha links anti-cancer cytotoxic chemotherapy to reactivation of hepatitis B virus. J Viral Hepatitis. 2013;20(1):34\u201341 [PMID: 23231082. https:\/\/doi.org\/10.1111\/j.1365-2893.2012.01622.x.","journal-title":"J Viral Hepatitis"},{"issue":"10","key":"1339_CR54","doi-asserted-by":"publisher","first-page":"e20719","DOI":"10.5812\/hepatmon.20719","volume":"14","author":"W Huang","year":"2014","unstructured":"Huang W, Zhao F, Huang Y, Li X, Zhu S, Hu Q, Chen W. Rapamycin enhances HBV production by inducing cellular autophagy. Hepatitis Monthly. 2014;14(10):e20719 [PMID: 25419217 PMCID: 4238155. https:\/\/doi.org\/10.5812\/hepatmon.20719.","journal-title":"Hepatitis Monthly"},{"issue":"1","key":"1339_CR55","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/hep.25602","volume":"56","author":"K Hoppe-Seyler","year":"2012","unstructured":"Hoppe-Seyler K, Sauer P, Lohrey C, Hoppe-Seyler F. The inhibitors of nucleotide biosynthesis leflunomide, FK778, and mycophenolic acid activate hepatitis B virus replication in vitro. Hepatology. 2012;56(1):9\u201316 [PMID: 22271223. https:\/\/doi.org\/10.1002\/hep.25602.","journal-title":"Hepatology"},{"issue":"9","key":"1339_CR56","doi-asserted-by":"publisher","first-page":"4578","DOI":"10.1128\/JVI.64.9.4578-4581.1990","volume":"64","author":"JH Ou","year":"1990","unstructured":"Ou JH, Bao H, Shih C, Tahara SM. Preferred translation of human hepatitis B virus polymerase from core protein- but not from precore protein-specific transcript. J Virol. 1990;64(9):4578\u201381 PMID: 2384923 PMCID: 247932.","journal-title":"J Virol"},{"issue":"2","key":"1339_CR57","doi-asserted-by":"publisher","first-page":"eaau7130","DOI":"10.1126\/sciadv.aau7130","volume":"5","author":"L Hou","year":"2019","unstructured":"Hou L, Zhao J, Gao S, Ji T, Song T, Li Y, Wang J, Geng C, Long M, Chen J, Lin H, Cai X, Cang Y. Restriction of hepatitis B virus replication by c-Abl-induced proteasomal degradation of the viral polymerase. Sci Advances. 2019;5(2):eaau7130 [PMID: 30775435 PMCID: 6365112. https:\/\/doi.org\/10.1126\/sciadv.aau7130.","journal-title":"Sci Advances"},{"issue":"15","key":"1339_CR58","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1200\/JCO.2009.21.9352","volume":"27","author":"YX Koo","year":"2009","unstructured":"Koo YX, Tan DS, Tan BH, Quek R, Tao M, Lim ST. Risk of hepatitis B virus reactivation in patients who are hepatitis B surface antigen negative\/antibody to hepatitis B core antigen positive and the role of routine antiviral prophylaxis. J Clin Oncol. 2009;27(15):2570\u20131; author reply 2571\u20132572 [PMID: 19364951. https:\/\/doi.org\/10.1200\/JCO.2009.21.9352.","journal-title":"J Clin Oncol"},{"key":"1339_CR59","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1471-230X-14-31","volume":"14","author":"M Masarone","year":"2014","unstructured":"Masarone M, De Renzo A, La Mura V, Sasso FC, Romano M, Signoriello G, Rosato V, Perna F, Pane F, Persico M. Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma. BMC Gastroenterol. 2014;14:31 [PMID: 24533834 PMCID: 3938973. https:\/\/doi.org\/10.1186\/1471-230X-14-31.","journal-title":"BMC Gastroenterol"},{"issue":"10","key":"1339_CR60","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/nm1096-1104","volume":"2","author":"B Rehermann","year":"1996","unstructured":"Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med. 1996;2(10):1104\u20138 PMID: 8837608.","journal-title":"Nat Med"},{"issue":"3","key":"1339_CR61","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/jmv.1890430314","volume":"43","author":"AP Catterall","year":"1994","unstructured":"Catterall AP, Murray-Lyon IM, Zuckerman AJ, Harrison TJ. Southern hybridisation analysis of HBV DNA in peripheral blood leucocytes and of different cell types: changes during the natural history and with interferon-alpha therapy in patients with hepatitis B virus infection. J Med Virol. 1994;43(3):269\u201375 PMID: 7931189.","journal-title":"J Med Virol"},{"issue":"6","key":"1339_CR62","doi-asserted-by":"publisher","first-page":"309","DOI":"10.7150\/ijms.5.309","volume":"5","author":"A Lisotti","year":"2008","unstructured":"Lisotti A, Azzaroli F, Buonfiglioli F, Montagnani M, Alessandrelli F, Mazzella G. Lamivudine treatment for severe acute HBV hepatitis. Int J Med Sci. 2008;5(6):309\u201312 PMID: 18974858 PMCID: 2574019.","journal-title":"Int J Med Sci"},{"issue":"12","key":"1339_CR63","doi-asserted-by":"publisher","first-page":"e0145746","DOI":"10.1371\/journal.pone.0145746]","volume":"10","author":"X Cheng","year":"2015","unstructured":"Cheng X, Guan W, Sun S, Li B, Li H, Kang F, Kang J, Yang D, Nassal M, Sun D. Stable human hepatoma cell lines for efficient regulated expression of nucleoside\/nucleotide analog resistant and vaccine escape hepatitis B virus variants and woolly monkey hepatitis B virus. PloS one. 2015;10(12):e0145746 [PMID: 26699621 PMCID: 4689378. https:\/\/doi.org\/10.1371\/journal.pone.0145746].","journal-title":"PloS one"},{"key":"1339_CR64","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s12876-014-0214-x","volume":"14","author":"F Morisco","year":"2014","unstructured":"Morisco F, Guarino M, La Bella S, Di Costanzo L, Caporaso N, Ayala F, Balato N. Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis. BMC Gastroenterol. 2014;14:214 [PMID: 25523080 PMCID: 4279461. https:\/\/doi.org\/10.1186\/s12876-014-0214-x.","journal-title":"BMC Gastroenterol"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-020-01339-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-020-01339-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-020-01339-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:44:46Z","timestamp":1625100286000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-020-01339-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,1]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1339"],"URL":"https:\/\/doi.org\/10.1186\/s12985-020-01339-5","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,1]]},"assertion":[{"value":"12 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Because no animals and patients were involved in this study, the Ethics approval not applicable in this section.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"89"}}